Company intelligence / Profile preview

MRC Biotech

North Sydney, New South Wales, Australia

Ownership: Private
Development stage: Other

Overview

MRC Biotech Pty Ltd was an Australian biotechnology company focused on the development of novel anticancer therapeutics through the repositioning of existing drugs. The company's lead program, MRC202, was a reformulated version of the anthelmintic drug albendazole, which was investigated in Phase 1 clinical trials for the treatment of malignant ascites and peritoneal cancers. MRC Biotech aimed to leverage the anti-tubulin properties of albendazole to inhibit tumor growth and reduce fluid accumulation in late-stage cancer patients. The company also explored a second candidate, MRC304, for similar oncology indications before its operations were discontinued in 2015.

Therapeutic areas: Oncology
Modalities: Small moleculeNanoparticle
Industry: Biotech

Drug pipeline

1 asset

MRC202

Unknown

Partnerships

Servcorp

Beyond the preview

Go deeper on MRC Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MRC Biotech.

Explore the full profile